Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00709735 · ClinicalTrials.gov registry record · Phase 4

A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol

A Phase 4 study of Posttraumatic Stress Disorder, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
23
Enrollment target
3
Study locations

NCT00709735 is a Phase 4 study of Posttraumatic Stress Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 23 participants, below the 112-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (79% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00709735, a Phase 4 study of Posttraumatic Stress Disorder, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
23 participants
Enrollment target
3
Study locations

Study Summary

The consolidation of learning is enhanced by adrenalin and other stress hormones. This memory enhancing effect is opposed by propranolol. In posttraumatic stress disorder (PTSD), a psychologically traumatic event may overstimulate stress hormones such as adrenalin, which in turn overly strengthen consolidation of the memory of the event, leading to an excessively powerful and persistent memory. Administration of propranolol after a psychologically traumatic event could reduce subsequent PTSD. Unfortunately, there exists a window of opportunity for influencing the consolidation of a traumatic event into long-term memory. In persons who have already developed PTSD, this would have closed months or years earlier. However, recent developments in animal research suggest that reactivation (retrieval) of a consolidated memory can return it to a labile state, from which it must be restabilized in order to persist. This process, which has been termed "reconsolidation," can be reduced in animals by propranolol. In a preliminary study performed by the PI and colleagues in Canada, civilian participants with PTSD described the traumatic event during a script preparation session, which served to reactivate their traumatic memory. They then received either propranolol or placebo. A week later, during script-driven imagery of their traumatic events, physiologic responses were smaller in the participants who had received post-reactivation propranolol compared to placebo, suggesting that the traumatic memory had been weakened by the propranolol. These results suggest that that post-reactivation propranolol recapitulates its effects on consolidation, this time by blocking reconsolidation of the traumatic memory. Several important questions remain unanswered. First, does propranolol also weaken traumatic memories in combat-related PTSD? Second, does this weakening effect only occur when the propranolol is given after combat memory reactivation? If not, this would refute the reconsoli

Interventions

  • DRUG Placebo
  • DRUG Propranolol

Study Locations (3)

Massachusetts

  • VA Medical Center - Bedford
  • Massachusetts General Hospital - Boston

New Hampshire

  • VA Medical Center - Manchester

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2007-05
Est. Completion 2010-08
Phase Phase 4

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00709735

The ClinicalTrials.gov registry entry for NCT00709735 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 112-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (79% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Posttraumatic Stress Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00709735 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New Hampshire.

Frequently Asked Questions

What is clinical trial NCT00709735 about?

NCT00709735 is a clinical study titled "A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol". The consolidation of learning is enhanced by adrenalin and other stress hormones. This memory enhancing effect is opposed by propranolol. In posttraumatic stress disorder (PTSD), a psychologically traumatic event may overstimulate stress hormones such as adrenalin, which in turn overly strengthen co...

What is the current status of trial NCT00709735?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 23 participants. The study started on 2007-05. Estimated completion is 2010-08.

What conditions does trial NCT00709735 study?

This clinical trial studies the following conditions: Posttraumatic Stress Disorder.

What interventions are being tested in trial NCT00709735?

The interventions under investigation include: Placebo (DRUG), Propranolol (DRUG).

Who is sponsoring clinical trial NCT00709735?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00709735 being conducted?

This trial has 3 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Posttraumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.